Short Interest in Aptose Biosciences Inc. (NASDAQ:APTO) Rises By 63.7%

Aptose Biosciences Inc. (NASDAQ:APTO) (TSE:APS) saw a large increase in short interest in February. As of February 28th, there was short interest totalling 122,600 shares, an increase of 63.7% from the February 13th total of 74,900 shares. Currently, 6.1% of the company’s stock are short sold. Based on an average daily trading volume, of 395,100 shares, the days-to-cover ratio is presently 0.3 days.

Aptose Biosciences Price Performance

NASDAQ APTO opened at $3.69 on Monday. Aptose Biosciences has a fifty-two week low of $2.39 and a fifty-two week high of $51.61. The stock’s 50-day moving average is $5.13 and its two-hundred day moving average is $8.04. The firm has a market cap of $7.90 million, a P/E ratio of -1.24 and a beta of 1.14.

Wall Street Analysts Forecast Growth

A number of equities analysts have recently weighed in on the stock. HC Wainwright reaffirmed a “buy” rating and issued a $60.00 price target on shares of Aptose Biosciences in a research note on Wednesday, February 12th. StockNews.com started coverage on Aptose Biosciences in a research report on Wednesday, March 5th. They issued a “sell” rating on the stock. Finally, Alliance Global Partners raised Aptose Biosciences to a “strong-buy” rating in a research note on Thursday, February 27th. One analyst has rated the stock with a sell rating, three have given a buy rating and one has issued a strong buy rating to the company’s stock. Based on data from MarketBeat.com, Aptose Biosciences currently has an average rating of “Moderate Buy” and an average target price of $130.00.

Institutional Inflows and Outflows

An institutional investor recently raised its position in Aptose Biosciences stock. Sigma Planning Corp grew its position in Aptose Biosciences Inc. (NASDAQ:APTO) (TSE:APS) by 71.3% during the third quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The firm owned 401,750 shares of the biotechnology company’s stock after purchasing an additional 167,282 shares during the quarter. Sigma Planning Corp owned approximately 2.22% of Aptose Biosciences worth $165,000 as of its most recent SEC filing. 26.62% of the stock is currently owned by institutional investors.

Aptose Biosciences Company Profile

Aptose Biosciences Inc, a clinical-stage biotechnology company, discovers and develops personalized therapies addressing unmet medical needs in oncology in Canada. Its lead clinical program is APTO-253, which is a Phase I clinical trial for the treatment of patients with relapsed or refractory hematologic malignancies.